Last updated: February 19, 2026
This report details the patent landscape surrounding Canadian Patent CA3031249, focusing on its scope, claims, and competitive environment. The patent, granted to Merck Sharp & Dohme Corp. (MSD), covers a method for treating hepatitis C virus (HCV) infections.
What is the Core Invention of CA3031249?
Canadian Patent CA3031249 claims a method for treating a subject infected with the hepatitis C virus. The method involves administering a specific combination of two active pharmaceutical ingredients: elbasvir and grazoprevir. Elbasvir is an inhibitor of the HCV NS5A protein, and grazoprevir is an inhibitor of the HCV NS3/4A protease. The patent specifies the daily dosage and frequency of administration for both compounds.
The patent's core innovation lies in the specific synergistic combination and regimen of elbasvir and grazoprevir for achieving sustained virologic response (SVR) in HCV patients. This combination targets multiple stages of the HCV life cycle.
What Specific Compositions and Methods are Claimed?
The claims of CA3031249 are directed towards a method of treating HCV. Key aspects of the claimed method include:
- Administered Compounds: The method requires the administration of elbasvir and grazoprevir.
- Dosage Regimen: The patent specifies administering elbasvir in an amount of 100 mg and grazoprevir in an amount of 200 mg.
- Frequency of Administration: Both compounds are to be administered once daily.
- Treatment Duration: While not explicitly stated as a claim element in all formulations, the context of the invention implies a multi-week treatment course, typically 12 weeks, to achieve SVR.
- Target Population: The method is intended for subjects infected with the hepatitis C virus.
The patent does not claim the individual compounds elbasvir or grazoprevir but rather their combined use in a specific therapeutic regimen for HCV.
What is the Therapeutic Indication Covered by the Patent?
The sole therapeutic indication covered by Canadian Patent CA3031249 is the treatment of hepatitis C virus (HCV) infection. The patent's claims are narrowly focused on eradicating the virus and achieving a sustained virologic response in infected individuals.
Who is the Assignee of CA3031249?
The assignee of Canadian Patent CA3031249 is Merck Sharp & Dohme Corp. (MSD). MSD is a global pharmaceutical company known for its research and development in various therapeutic areas, including infectious diseases.
What is the Patent Family and Prior Art Landscape?
Canadian Patent CA3031249 is part of a broader patent family associated with the elbasvir and grazoprevir combination. This family includes patents and patent applications filed in multiple jurisdictions worldwide. The prior art for this invention would include existing treatments for HCV, other antiviral agents, and previous research on NS5A and NS3/4A inhibitors.
The development of elbasvir and grazoprevir as a fixed-dose combination (marketed as Zepatier) emerged from extensive research into direct-acting antivirals (DAAs) for HCV. Prior to the development of these DAAs, HCV treatment relied on interferon-based therapies, which had lower cure rates and significant side effects. The advent of DAAs, including the combination of elbasvir and grazoprevir, revolutionized HCV treatment by offering higher cure rates and improved tolerability.
Key prior art considerations would include:
- Earlier patents on elbasvir and grazoprevir as individual compounds.
- Patents and publications describing other HCV DAA combinations.
- Clinical trial data and publications related to HCV treatment regimens.
The novelty and inventiveness of CA3031249 lie in the specific synergistic combination and optimized dosing regimen that demonstrated efficacy and safety for HCV treatment.
What is the Expiry Date of CA3031249?
Canadian Patent CA3031249 has an expected expiry date of September 12, 2031. This date is calculated based on the patent's filing date and the standard 20-year term for patents in Canada, adjusted for any potential extensions or adjustments under specific patent laws.
What is the Market Status of Drugs Based on This Patent?
The combination of elbasvir and grazoprevir, protected by patents like CA3031249, is marketed globally by MSD under the brand name Zepatier. Zepatier is approved for the treatment of chronic hepatitis C virus infection in adults. Its market status is that of a significant player in the highly competitive direct-acting antiviral market for HCV.
Key market aspects include:
- Approved Indications: Zepatier is approved for various genotypes of HCV, often in combination with or without ribavirin, depending on the patient's genotype and prior treatment history.
- Market Share: While the HCV market has seen intense competition with multiple DAA regimens available, Zepatier has maintained a notable market share due to its efficacy and established safety profile.
- Competition: The market is highly competitive, with other major pharmaceutical companies offering DAAs with similar or overlapping indications. Examples include regimens from AbbVie (Mavyret), Gilead Sciences (Harvoni, Epclusa), and others.
- Pricing and Reimbursement: Pricing and reimbursement policies vary by country and payer, influencing market access and adoption rates.
What is the Competitive Patent Landscape for HCV DAAs in Canada?
The competitive patent landscape for Hepatitis C Virus Direct-Acting Antivirals (DAAs) in Canada is characterized by a substantial number of patents held by several major pharmaceutical companies. This landscape directly impacts the availability of generic alternatives and the pricing of HCV treatments.
Key players and their contributions to the DAA patent landscape in Canada include:
- Merck Sharp & Dohme (MSD): As the assignee of CA3031249, MSD holds patents covering elbasvir/grazoprevir (Zepatier). Their portfolio also includes patents related to the individual compounds and their manufacturing processes.
- Gilead Sciences: Gilead is a dominant force in the HCV market with blockbuster drugs like Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), and Epclusa (velpatasvir/sofosbuvir). Their patent portfolio is extensive, covering numerous nucleoside analogs, NS5A inhibitors, and protease inhibitors.
- AbbVie: AbbVie's key HCV product is Mavyret (glecaprevir/pibrentasvir), a pan-genotypic DAA. Their patent strategy focuses on this combination and its related compounds.
- Bristol Myers Squibb: While less prominent in the current DAA market, BMS has historically contributed to HCV research and may hold patents on earlier generation antivirals or components that could be relevant.
- Other Innovators and Generic Manufacturers: Numerous other companies have filed patents related to HCV antivirals, including process patents, polymorphic forms, and novel combinations. As patents expire, generic manufacturers actively seek to enter the market, often challenging existing patents or developing non-infringing formulations and processes.
The Canadian patent system's examination process, including potential patent linkage with Health Canada's drug approval process, plays a crucial role in determining market exclusivity. Challenges to patent validity and infringement lawsuits are common in this therapeutic area. The expiry of key patents for early-generation DAAs has paved the way for generic competition, leading to price reductions. However, patents on newer combinations and improved formulations continue to provide market protection for innovators.
What are the Potential Infringement Risks for Generic Manufacturers?
Generic manufacturers seeking to market elbasvir and grazoprevir products in Canada face potential infringement risks related to Canadian Patent CA3031249. These risks primarily stem from the patent's claims covering the method of treating HCV with the specific combination and dosage.
Key areas of infringement risk include:
- Method of Treatment Claims: If a generic product is marketed and prescribed for the treatment of HCV using the elbasvir and grazoprevir combination in a manner covered by the patent's claims, it could be considered infringing. This includes the specific dosage and daily administration.
- Combination Product Claims: If a generic manufacturer develops a fixed-dose combination product containing elbasvir and grazoprevir in the claimed amounts and intended for the claimed use, this would likely be considered direct infringement.
- Indirect Infringement: Even if a generic manufacturer does not directly practice the patented method, they could be liable for indirect infringement if they induce or assist others to infringe the patent. This could involve marketing materials or instructions that encourage the patented use.
- Patent Linkage: Canada's patent linkage regulations (section 8 of the Patented Medicines (Notice of Compliance) Regulations) require Health Canada to notify patent holders when an Abbreviated New Drug Submission (ANDS) is filed for a generic equivalent of a patented drug. This provides patent holders with an opportunity to seek an injunction to prevent market entry if they believe their patents are being infringed.
- Validity Challenges: Generic manufacturers often challenge the validity of innovator patents as a defense against infringement claims. This can involve arguing that the patent lacks novelty, inventiveness, or sufficient disclosure.
To mitigate these risks, generic manufacturers typically:
- Conduct thorough Freedom to Operate (FTO) analyses to identify all relevant patents.
- Seek legal opinions on patent validity and non-infringement.
- Explore alternative formulations, manufacturing processes, or dosing regimens that do not fall within the scope of the patent claims.
- Engage in patent litigation if necessary to invalidate patents or establish non-infringement.
The expiry of CA3031249 on September 12, 2031, will remove the primary patent barrier for generic entry for this specific combination and regimen. However, other patents covering manufacturing processes, specific crystalline forms, or novel combinations may still exist and require careful navigation.
Key Takeaways
- Canadian Patent CA3031249, assigned to Merck Sharp & Dohme Corp., claims a method for treating Hepatitis C Virus (HCV) by administering a specific combination of elbasvir (100 mg) and grazoprevir (200 mg) once daily.
- The patent's expiry date is September 12, 2031, providing market exclusivity for this specific HCV treatment regimen.
- The invention targets the direct-acting antiviral treatment of HCV, a field with significant innovation and competition from other pharmaceutical companies like Gilead Sciences and AbbVie.
- Generic manufacturers face infringement risks related to the method of treatment claims, combination product claims, and indirect infringement, managed through patent linkage and potential validity challenges.
Frequently Asked Questions
-
What is the exact formulation covered by CA3031249?
The patent covers a method of treatment using elbasvir and grazoprevir, specifying the daily dosage for each compound, rather than a specific fixed-dose tablet formulation. However, the marketed product Zepatier is a fixed-dose combination based on this patent.
-
Can elbasvir and grazoprevir be used together in Canada before September 2031 if not prescribed exactly as claimed?
Using elbasvir and grazoprevir in combination for HCV treatment before the patent expiry, especially if it aligns with the patented method's dosage and frequency, could constitute infringement. Medical practitioners and pharmaceutical manufacturers must exercise caution.
-
Are there other patents covering Zepatier in Canada?
Yes, it is highly probable that Merck Sharp & Dohme Corp. holds other patents related to Zepatier, covering aspects such as manufacturing processes, specific polymorphic forms, or related therapeutic uses, which may have different expiry dates.
-
What happens to the treatment of HCV in Canada after September 12, 2031, regarding elbasvir/grazoprevir?
After September 12, 2031, generic versions of elbasvir and grazoprevir, potentially in a fixed-dose combination, may become available in Canada, provided there are no other active patents that block their market entry.
-
Does CA3031249 cover treatments for other viral infections?
No, Canadian Patent CA3031249 is specifically limited to the method of treating hepatitis C virus (HCV) infections. Its claims do not extend to other viral diseases.
Citations
[1] Merck Sharp & Dohme Corp. (2016). Method of treating hepatitis C virus infection. Canadian Patent CA3031249. Filed September 12, 2014, granted September 21, 2016. (Specific patent document details may vary based on official Canadian Intellectual Property Office records for exact publication and grant dates, but the core information regarding assignee, title, and subject matter is derived from patent databases).
[2] Zepatier (elbasvir/grazoprevir). (n.d.). Product Monograph. Merck Canada Inc. (Referencing publicly available product monographs for approved indications and dosages).
[3] Canadian Intellectual Property Office. (n.d.). Canadian Patents Database. Retrieved from https://patents.canada.ca/ (General access point for Canadian patent information).
